Search

Coloplast A-S (Class B)

Abrir

562.4 0.32

Visão Geral

Variação de preço das ações

24h

Atual

Mín

559

Máximo

566

Indicadores-chave

By Trading Economics

Rendimento

70M

875M

Vendas

2M

7B

P/E

Médio do Setor

34.472

87.826

EPS

3.88

Rendimento de Dividendos

4.24

Margem de lucro

12.572

Funcionários

16,744

EBITDA

2B

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+11.86% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

4.24%

2.26%

Próximos Ganhos

6 de fev. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

2.5B

125B

Abertura anterior

562.08

Fecho anterior

562.4

Coloplast A-S (Class B) Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de jan. de 2026, 23:11 UTC

Ganhos

Samsung Electronics Expects Record Fourth-Quarter Profit Beat

7 de jan. de 2026, 22:55 UTC

Grandes Movimentos do Mercado

Defense Stocks Rebound After Trump Says He Wants $1.5 Trillion Military Budget in 2027

7 de jan. de 2026, 21:39 UTC

Grandes Movimentos do Mercado

Raytheon Down Following Trump Post Criticizing Company

7 de jan. de 2026, 20:13 UTC

Grandes Movimentos do Mercado

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

7 de jan. de 2026, 20:03 UTC

Grandes Movimentos do Mercado

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Executive Pay

7 de jan. de 2026, 23:46 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 de jan. de 2026, 23:46 UTC

Conversa de Mercado

Nikkei May Decline as China-Japan Tensions Linger -- Market Talk

7 de jan. de 2026, 23:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 5th Update

7 de jan. de 2026, 23:34 UTC

Conversa de Mercado

Gold Edges Higher Amid Lingering Geopolitical Risks -- Market Talk

7 de jan. de 2026, 23:29 UTC

Aquisições, Fusões, Aquisições de Empresas

Constellation Closes Deal for Calpine, Creating Biggest Electricity Generator -- Barrons.com

7 de jan. de 2026, 22:48 UTC

Conversa de Mercado

Infratil's Discount to Net Asset Value Too Good to Ignore -- Market Talk

7 de jan. de 2026, 22:46 UTC

Ganhos

Samsung Electronics Estimates 2025 Rev KRW332.770T Vs KRW300.870T >005930.SE

7 de jan. de 2026, 22:45 UTC

Ganhos

Samsung Electronics Estimates 2025 Oper Pft KRW43.530T Vs KRW32.730T >005930.SE

7 de jan. de 2026, 22:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Revolution Medicines Draws Takeover Interest -- 2nd Update

7 de jan. de 2026, 22:42 UTC

Ganhos

Samsung Electronics 4Q Oper Pft Estimate Beat FactSet-Compiled Consensus Forecast

7 de jan. de 2026, 22:41 UTC

Ganhos

Samsung Electronics Sees 4Q Oper Pft KRW20.000T Vs KRW6.490T >005930.SE

7 de jan. de 2026, 22:41 UTC

Ganhos

Samsung Electronics Sees 4Q Rev KRW93.000T Vs KRW75.790T >005930.SE

7 de jan. de 2026, 22:40 UTC

Grandes Movimentos do Mercado

Defense Stocks Rebound After Trump Says He Wants $1.5T Military Budget in 2027

7 de jan. de 2026, 22:31 UTC

Conversa de Mercado

Macro Tailwinds Strengthen for Chalice Mining -- Market Talk

7 de jan. de 2026, 22:22 UTC

Conversa de Mercado

Northern Star's Run of Disruptions Increasingly a Concern -- Market Talk

7 de jan. de 2026, 22:01 UTC

Conversa de Mercado

Valuations of New Zealand Property Stocks Supportive -- Market Talk

7 de jan. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

7 de jan. de 2026, 21:46 UTC

Conversa de Mercado

Northern Star's Revised Guidance Looks Achievable -- Market Talk

7 de jan. de 2026, 21:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Eli Lilly to Buy Ventyx Biosciences for $14 a Share >LLY VTYX

7 de jan. de 2026, 21:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-mediated Diseases >LLY VTYX

7 de jan. de 2026, 21:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 4th Update

7 de jan. de 2026, 20:29 UTC

Aquisições, Fusões, Aquisições de Empresas

AbbVie Near Deal for Revolution Medicines -- Update

7 de jan. de 2026, 20:27 UTC

Conversa de Mercado

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

7 de jan. de 2026, 19:58 UTC

Conversa de Mercado

Oil Falls As U.S. to Receive Sanctioned Venezuelan Crude -- Market Talk

7 de jan. de 2026, 19:48 UTC

Grandes Movimentos do Mercado

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Exec Pay

Coloplast A-S (Class B) Previsão

Preço-alvo

By TipRanks

11.86% parte superior

Previsão para 12 meses

Média 901.38 DKK  11.86%

Máximo 1,056 DKK

Mínimo 720 DKK

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Coloplast A-S (Class B) - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

8 ratings

2

Comprar

4

Manter

2

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat